UnknownNCT03423680
A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Depression in bipolarity
Medication studyAges 19–70South Korea
Understand this study
Who could participate?
This study is for people with bipolarity. Listed age limits: 19 years to 70 years. Other eligibility criteria apply.
- Listed locations
- SeoulSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: February 22, 2018
- Recruitment status
- Unknown
- Enrollment listed in the registry
- 390
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- South Korea
- Age range
- From 19 Years to 70 Years
- Official registry ID
- NCT03423680
- Official title
Show the full official title
A Multicenter, Randomized, Double Blind, Placebo-controlled, Parallel Group, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Treatment of Major Depressive Episode Associated With Bipolar I or II Disorder
Recruitment & locations
Status unknownThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Seoul
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Korea Otsuka Pharmaceutical Co., Ltd., a pharmaceutical company.
Does this study involve medication?
Yes. The study involves medication, including Abilify 2, 5, 10, 15mg (Tablet) and Placebo of Abilify 2, 5, 10, 15mg (Tablet).
Who can participate?
This study is for people with bipolarity. Listed age limits: 19 years to 70 years. Other eligibility criteria apply.
